Tag: AIM ImmunoTech Inc.

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to AIM ImmunoTech Inc.

AIM ImmunoTech (NYSE:AIM) Shares Down 8.3%

Added to Collection on: 2019-12-04 10:48:45

Tags for this article:

AIM ImmunoTech
New York Stock Exchange
N-Shares
Companies
Stock market
Economy
AIM ImmunoTech Inc.

Click the tags to see associated articles and topics

View Article Details
Investor confidence shakens after AIM ImmunoTech Inc. (NYSE:AIM) share prices loss $

Added to Collection on: 2020-07-26 20:56:15

Tags for this article:

Money
Finance
Stock market
Stock
Financial markets
Short
Corporate finance
Financial ratios
Fundamental analysis
Earnings per share
Initial public offering
Mutual fund
AIM ImmunoTech Inc.

Click the tags to see associated articles and topics

View Article Details
AIM ImmunoTech Inc. (AMEX: AIM) Is Getting Increasingly Hard To Ignore

Added to Collection on: 2020-07-30 18:52:30

Tags for this article:

Financial markets
Stock market
Finance
Financial economics
Stock
IShares
Insider trading
Exchange-traded fund
AIM ImmunoTech Inc.

Click the tags to see associated articles and topics

View Article Details
AIM ImmunoTech Inc. (NYSE:AIM) Jumps 5.02%, But Additional Rally May Be Imminent

Added to Collection on: 2020-08-05 20:22:30

Tags for this article:

Financial markets
Finance
Money
Stock market
Equity securities
Corporate finance
Financial regulation
Short
Valuation
Stock
Share
Mutual fund
AIM ImmunoTech Inc.

Click the tags to see associated articles and topics

View Article Details
Key turning points to Take off: AIM ImmunoTech Inc. (AIM), CME Group Inc. (CME)

Added to Collection on: 2020-08-21 00:41:15

Tags for this article:

Financial markets
Finance
Money
Futures exchanges
Futures markets
CME Group
Chicago Board of Trade
Market data
Futures contract
Morgan Stanley
Stock
Chicago Mercantile Exchange
AIM ImmunoTech Inc.
MORGAN STANLEY & CO. LLC

Click the tags to see associated articles and topics

View Article Details
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 ...

Added to Collection on: 2024-04-29 15:55:02

Tags for this article:

Orphan drugs
Rintatolimod
AIM ImmunoTech
Cancer immunotherapy
Checkpoint inhibitor
Durvalumab
Private Securities Litigation Reform Act
PD-L1
Forward-looking statement
AIM ImmunoTech Inc.
Ampligen

Click the tags to see associated articles and topics

View Article Details
Book a Demo